Echo Therapeutics,  Inc. (OTCBB: ECTE) – a stock that I personally thought would be trading above $2 by now, recently had its Symphony™ trans-dermal Glucose monitoring system was featured in a March 31, 2010 online magazine article in Scientific American entitled “This Really Won’t Hurt a Bit: Wireless Sensor Promises Diabetics Noninvasive Blood Sugar Readings,” by Larry Greenemeier. The article is certainly worth a read, and if Echo’s Symphony offering can succeed where past attempts and continuous blood glucose monitoring systems have failed, could be very positive for PPS. Management has recently issued some fairly lofty goals for 2010, if and they are met, $1.55 will likely seem like a dream 6 to 12 months down the road.

Echo Therapeutics Inc. (OTCBB: ECTE) appears to have bounced off its 20 Moving Average and is moving back upward. Watch for a push towards new 52 week highs.

Click Here to View Report/Buy Recommendation

Below is an another analysis from StockTA.com.  ECTE’s signals have been increasing since I began watching it, which indicates that the trend the symbol is displaying is VERY BULLISH!

Overall: Very Bullish  (.53)  -  Short: Very Bullish (.66)  -   Intermediate: Very Bullish (.50)   -   Long: (.43)

Read below for more in-depth trending and indicator charting & data – FYI: This is definately worth a look!

(more…)

Echo Therapeutics, Inc. (OTCBB: ECTE) is poised to move higher. By hitting a new 52-week high, ECTE has triggered major accumulation among traders and things are heating up.   Remember, there are countless indicators that are very optimistic regarding ECTE’s bullish trend. So, if this trend continues then it could cause shares to increase. Below is an updated snapshot from barchart.com…

(more…)

Here’s a link to Echo Therapeutics (OTCBB: ECTE) CEO Patrick H. Mooney, M.D’s presentation this week at the OneMed Finance Forum in San Francisco: http://www.ustream.tv/recorded/3953983

This gives a gret description of the company, its key products/technologies, and core markets in a quick and understandable preso. Judging from this update, things are certainly looking up for Echo this year. Enjoy!

Echo Therapeutics, Inc. (OTCBB: ECTE) made it to new 18 month highs yesterday, hitting $2.04 at one point and closing at a new 52 week high of $2.02. Pre-market trading is looking strong so far at $2.06 We suspect there will be excitement at the open again this morning, with another gap up. Now that we have a break of the elusive $2 mark, more new highs should be coming daily.

(more…)

ECTE got within ONE PENNY of its 52 week high yesterday.Gaping up 18 cents and tapping on $1.99 before pulling back to close at $1.83. With the path now cleared to $1.99, we are looking for a break of the elusive $2 mark in the coming days with a break out that could reach as high as $3!

All of the top-rated companies in stock market history share one common characteristic: A product or service breakthrough that improves life for a significant percentage of the world. Echo Therapeutics, Inc. (OTCBB: ECTE) is striving to become one of those companies by making life easier for the world’s 180 million Diabetics. The company plans to seek final FDA approval in 2010 for its “Symphony” device – the first needle-free product of its kind.

“Necessity is the mother of invention” – Plato

As a sharp fella by the name of Plato once said “necessity is the mother of invention”. In ECTE’s case, necessity is the need for the world’s surging Diabetic population to refrain from being pincushions. Most sufferers cite multiple daily needle sticks as the worst part of the disease. Therefore, it seems very likely that the first product capable of monitoring glycemic levels without needles would be extremely popular. While we’ve yet to develop a cure for deadly diseases like Cancer, HIV, recent advancements have helped drastically improve quality of life for those afflicted.

Innovation drove some huge PPS increases for leading medical device makers in ‘09, many of which recently gained FDA-approval for new products. A few high-growth scenarios that Echo Therapeutics could mimic if it does in fact bring 1 or 2 products to market over the next 12-18 months include:

Endologix (Nasdaq: ELGX) Recently gained FDA approval and began commercial production for its IntuiTrak® stent graft delivery system for aortic aneurysms. PPS rose from a low of $1.63 to a high of $4.83 on 12/29. Much like ECTE’s technology, ELGX’s product addresses the shortcomings of first generation devices and facilitates major improvements to patient comfort, quality of treatment, and mortality rates.

American Shared Hospital Services (AMEX: AMS) PPS jumped from $1.00 to $2.95 in 2009 as the company’s FDA-approved Gamma Knife, non-invasive radio-surgery Cancer treatment emerged as a best-in-class offering. It is important to note that AMS likely generated less than $20 million in annual sales during ‘09 with systems in place at roughly 19 medical centers in 17 U.S. states. While the company’s product is solid and future potential exciting, ECTE likely has more mass market appeal and should be able to generate substantially higher revenues once or, two, or three FDA-approved products reach market.

Candela Corp. (Nasdaq: CLZR) – Shares of the pioneer in laser-based cosmetic surgery devices surged from $.53 to $2.68 on expectations of a merger with Syneron (Nasdaq: ELOS) a leading global aesthetic device maker. The deal closed last week and the future looks bright for the new Syneron, which now boasts likely the strongest product offering and global reach in its market niche.

 Other prime examples of how transformational healthcare innovation translates into profits for investors include:

Merck & Co. (NYSE: MRK)- shares nearly doubled from the October 2006 announcement that the company received FDA approval for the first ever vaccine for human pappilomavirus (HPV) infection.

ECTE holds the  potential to begin commercial production of one, perhaps two FDA-approved products in 2010 that have an opportunity to command a substantial share of a combined >$12 billion target market. Therefore, we feel strongly that this year, Echo Therapeutics is positioned to deliver the type of returns generated by leading medical device companies including ELGX, AMS, and ELOS in 2009.